Browne L Daniel 4
4 · Revance Therapeutics, Inc. · Filed Feb 20, 2019
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Tax Payment
Common Stock
2019-02-15$17.69/sh−3,154$55,794→ 174,389 total - Sale
Common Stock
2019-02-19$17.68/sh−5,446$96,285→ 168,943 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]Represents the number of shares withheld by and surrendered to the issuer on February 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award (the "RSA") for 25,800 shares. The RSA vests in three equal annual installments from February 15, 2017, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- [F3]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.